Media Center

Media Center

Sandoz TV Episode 18: Trailer

Find out what to expect from the newest episode of Sandoz TV.

Global News Sandoz Around the World Sandoz in the Media

Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®

Holzkirchen, December 08, 2014

Sandoz, a Novartis company, announced today Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®

Sandoz receives approvals in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, November 19, 2014

Sandoz announces today that the pharmaceutical regulatory authorities in Ireland and the Czech Republic have granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

Sandoz launches ready-to-use oral formulation of ACC® cough medicine in Ukraine

Kiev, November 12, 2014

Sandoz, the generic pharmaceutical division of Novartis, today announces the launch in Ukraine of a new ready-to-use oral formulation of ACC® cough medicine.

Sandoz launches first generic version of cyclophosphamide injection, USP

Princeton, November 10, 2014

Sandoz today announced the US market introduction of cyclophosphamide injection, USP.

Sandoz receives approvals in Baltics for innovative respiratory inhaler AirFluSal® Forspiro®

Holzkirchen, November 04, 2014

Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).


More News